Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments and Licenses - Available for Sale Investments, Sale of Investments and Warrants and Options Narrative (Details)

v3.8.0.1
Acquisitions, Investments and Licenses - Available for Sale Investments, Sale of Investments and Warrants and Options Narrative (Details) - USD ($)
shares in Millions, $ in Millions
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Rxi Pharmaceuticals Corporation    
Investment [Line Items]    
Ownership percentage 2.00%  
ChromaDex    
Investment [Line Items]    
Ownership percentage 1.00%  
MabVax    
Investment [Line Items]    
Ownership percentage 4.00%  
Number of shares into which warrants may be converted (in shares) 0.2  
ARNO    
Investment [Line Items]    
Ownership percentage 5.00%  
Xenetic Biosciences, Inc.    
Investment [Line Items]    
Available for sale securities other than temporary impairment $ 0.6  
Number of shares into which warrants may be converted (in shares) 0.5  
Neovasc    
Investment [Line Items]    
Number of shares into which warrants may be converted (in shares) 1.0  
BioCardia, Inc.    
Investment [Line Items]    
Ownership percentage 5.00%  
Number of shares into which warrants may be converted (in shares) 5.0  
Cocrystal    
Investment [Line Items]    
Number of shares into which warrants may be converted (in shares) 1.0  
Sevion    
Investment [Line Items]    
Number of shares into which warrants may be converted (in shares) 0.3  
InCellDx, Inc    
Investment [Line Items]    
Number of shares into which warrants may be converted (in shares) 0.7  
Rxi    
Investment [Line Items]    
Number of shares into which warrants may be converted (in shares) 0.2  
Xenetic and RXi    
Investment [Line Items]    
Available for sale securities other than temporary impairment   $ 3.9